首页> 外文期刊>Polish Journal of Microbiology >Evaluation of a Salmonella Strain Isolated from Honeybee Gut as a Potential Live Oral Vaccine Against Lethal Infection of Salmonella Typhimurium
【24h】

Evaluation of a Salmonella Strain Isolated from Honeybee Gut as a Potential Live Oral Vaccine Against Lethal Infection of Salmonella Typhimurium

机译:从蜜蜂肠道中分离的沙门氏菌菌株作为潜在活性口腔疫苗对抗致死致命感染沙门氏菌的致死感染

获取原文
获取原文并翻译 | 示例
           

摘要

In this research, Salmonella species were isolated from the animal, insect and human enteric sources in Faisalabad, Punjab, Pakistan. These species were characterized by different microbiological and molecular techniques including polymerase chain reaction (PCR) by amplification of the 16S rRNA gene. Furthermore, sequencing of the amplicons confirmed all ten isolates as Salmonella strains. The antigenic cross-reactivity was found maximum between the HB1 (strain isolated from honeybee) antiserum and its antigen with an antibody titer of 1:128, while the HB1 antiserum showed a cross-reactive titer range of 1:8 to 1:64. On the basis of the highest geometric mean titer (GMT) shown by the antiserum of the HB1 antigen, it was selected as the best candidate for a cross-reactive live Salmonella oral antigen. Moreover, the HB1 antigen was used a live oral antigen (1 x 10(10) CFU/ml) in a safety test in rabbits and proved to be avirulent. During the animal trial, three different oral doses of the HB1 live oral antigen were evaluated in four different rabbits' groups (R1, R2, R3, and R4). The dose number 2 of 0.5 ml (two drops orally and repeated after one week) gave the best GMT measured by indirect hemagglutination (IHA) as compared to the other two doses, while R4 group was kept as control. Results of the challenge protection test also validated the efficacy of the double dose of the HB1 live vaccine, which gave the highest survival percentage. Results of this study lay the foundation for a potential cross-reactive live oral Salmonella vaccine that has proved to be immunogenic in rabbits.
机译:在这项研究中,沙门氏菌的物种与巴基斯坦邦普斯​​巴拉巴邦巴萨巴巴德的动物,昆虫和人肠道来源分离出来。这些物种的特征在于通过扩增16S rRNA基因的不同微生物和分子技术,包括聚合酶链反应(PCR)。此外,扩增子的测序证实了所有十个分离物作为沙门氏菌菌株。在HB1(从蜜蜂分离的菌株)抗血清之间的抗原交叉反应性最大,其抗体滴度为1:128,而HB1抗血清显示出1:8至1:64的交叉反应性滴度范围。基于HB1抗原的抗血清所示的最高几何平均滴度(GMT)的基础,选择作为交叉反应活性沙门氏菌口服抗原的最佳候选者。此外,HB1抗原在兔子的安全试验中使用活性口服抗原(1×10(10)CFU / mL),并证明是无毒的。在动物试验期间,在四个不同的兔子组(R1,R2,R3和R4)中评估三种不同口服剂量的HB1活性口服抗原。与其他两剂相比,0.5ml(两滴口服并重复)的0.5ml(两滴口服并重复),使R4基团保持下血凝血凝(IHA)。挑战保护试验的结果还验证了HB1活疫苗的双剂量的疗效,这给出了最高的存活率。该研究的结果为已被证明是兔子免疫原性的潜在交叉反应性活产口疫苗的基础。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号